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Background Optimal management of coronary artery disease (CAD) in patients undergoing TAVI is uncertain. We report outcome of CAD 
management options in TAVI patients in a single centre.
Methods Eighty three consecutive patients who underwent TAVI 2007 to 2010 were included. Patients were grouped by presence of significant CAD 
(>70% stenosis) and if percutaneous coronary intervention (PCI) was performed before TAVI. Duke Myocardial Jeopardy Score (DMJS) was used to 
estimate myocardium at ischemic risk and grouped to low (4 or less) and high (more than 4) DMJS. Outcome measures included death, myocardial 
infarction, revascularization post TAVI, changes in Canadian Cardiac Society (CCS) and New York Heart Association (NYHA) class.
Results Follow-up was 9.4 ± 0.1 months. Forty two patients had CAD; 22 had PCI prior to TAVI and 20 were treated medically. Baseline 
characteristics were similar except PCI group had higher CCS score (2.7 ± 0.7 vs 2.1 ± 1.1). PCI group had more left anterior descending (68.2% vs 
15.0%), left main PCI (13.6% vs 0.0%) and higher DMJS (4.8 vs 3.2, p=0.033). PCI related myocardial infarction and any biomarker elevation prior 
to TAVI was 27.3% and 40.9%. There was minimal improvement of CCS score post PCI (-0.1 ± 0.6). There were no differences in clinical events, need 
for additional coronary artery revascularization or improvement in NYHA and CCS classes post TAVI in both groups up to 6 months. Composite death 
and myocardial infarction rates were lower for low DMJS group at time of TAVI (15.8% vs 25.0%, p=0.532).
Conclusion Outcome of TAVI were not significantly different whether or not PCI was done prior to TAVI although PCI group had significantly higher 
DMJS compared to medical group. Medically treated patients had significant symptomatic improvement with TAVI alone, low rates of death (0%), 
myocardial infarction (10%) during TAVI or revascularization post TAVI (5%).
In severe aortic stenosis patients, PCI is high risk and it is prudent to select those who will benefit most from PCI prior to TAVI. . Low DMJS during TAVI 
is associated with lower rates event rates. DMJS used as a surrogate measurement of myocardium at risk can be a useful adjunct to stratify patients 
for PCI prior to TAVI.
